Non-invasive prenatal testing: what an obstetrician needs to know

Mishu Mangla


No field in obstetrics has seen such fast advancement, as the field of prenatal screening and diagnosis. A wide variety of tests are available today, and this at times becomes confusing both for the patient and the treating doctor that which screening test would be best suited in the given circumstances. Non-invasive prenatal screening, with its numerous advantages is rapidly becoming the test of first choice, especially in the affording set of population.  Although, the test has a very high sensitivity and a very good positive predictive value, this too suffers from some disadvantages which should be clear to the obstetrician ordering the test. A good knowledge about the test, the ideal target population in which this should be offered as the primary screening tool and limitations of the test should be known to all practicing obstetricians and primary health care providers. The current review aims to provide a simplified and updated knowledge regarding non-invasive prenatal testing (NIPT), its major advantages and disadvantages and summarizes the role of ultrasound in patients with negative NIPT.


Non-invasive prenatal testing, Prenatal screening, Antenatal screening

Full Text:



Committee on Practice Bulletins—Obstetrics, Committee on Genetics, and the Society for Maternal-Fetal Medicine. ACOG practice bulletin number 163: screening for fetal aneuploidy. Obstet Gynecol. 2016;127:e123-37.

Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015;372:1589-97.

Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. CARE Study Group. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014;370:799-80.

Gil MM, Akolekar R, Quezada MS, Bregant B, Nicolaides KH. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: meta-analysis. Fetal Diagn Ther. 2014;35:156-73.

Lo YM, Corbetta N, Chamberlain PF, Rai V, Sargent IL, Redman CW, et al. Presence of fetal DNA in maternal plasma and serum. Lancet. 1997;350(9076):485-7.

Bischoff FZ, Sinacori MK, Dang DD, Marquez-Do D, Horne C, Lewis DE, et al. Cell-free fetal DNA and intact fetal cells in maternal blood circulation: implications for first and second trimester non-invasive prenatal diagnosis. Hum Reprod Update. 2002;8(6):493-500.

Illanes S, Denbow M, Kailasam C, Finning K, Soothill PW. Early detection of cell-free fetal DNA in maternal plasma. Early Hum Dev. 2007;83(9):563-6.

Canick JA, Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE. The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn. 2013;33(7):667-74.

Ashoor G, Syngelaki A, Poon LC. Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol. 2013;41(1):26-32.

Pantiukh KS, Chekanov NN, Zaigrin IV, Zotov AM, Mazur AM, Prokhortchouk EB. Report on noninvasive prenatal testing: classical and alternative approaches. F1000Research. 2016;5.

Cuckle H, Benn P, Pergament E. Cell-free DNA screening for fetal aneuploidy as a clinical service. Clin Biochem. 2015;48(15):932-41.

Hall MP, Hill M, Zimmermann B, Sigurjonsson S, Westemeyer M, Saucier J, et al. Non-invasive prenatal detection of trisomy 13 using a single nucleotide polymorphism- and informatics-based approach. PLoS One. 2014;9:e966-77.

Ryan A, Hunkapiller N, Banjevic M, Vankayalapati N, Fong N, Jinnett KN et al. Validation of an Enhanced Version of a Single-Nucleotide Polymorphism-Based Noninvasive Prenatal Test for Detection of Fetal Aneuploidies. Fetal Diagn Ther. 2016;40(3):219-23.

Rieneck K, Clausen FB, Dziegiel MH. Noninvasive Antenatal Determination of Fetal Blood Group Using Next-Generation Sequencing. Cold Spring Harb Perspect Med. 2015;6(1):a023093.

Ma D, Yuan Y, Luo C, Wang Y, Jiang T, Guo F et al. Noninvasive prenatal diagnosis of 21-Hydroxylase deficiency using target capture sequencing of maternal plasma DNA. Sci Rep. 2017;7(1):7427.

Amicucci P, Gennarelli M, Novelli G, Dallapiccola B. Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma. Clin Chem. 2000;46(2):301-2.

Li Y, Page-Christiaens GC, Gille JJ, Holzgreve W, Hahn S. Non-invasive prenatal detection of achondroplasia in size-fractionated cell-free DNA by MALDI-TOF MS assay. Prenat Diagn. 2007;27(1):11-7.

Gil MM, Galeva S, Jani J, Konstantinidou L, Akolekar R, Plana MN et al. Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis. Ultrasound Obstet Gynecol. 2019;53(6):734-42.

Beulen L, Faas BHW, Feenstra I, van Vugt JMG, Bekker MN. Clinical utility of non-invasive prenatal testing in pregnancies with ultrasound anomalies. Ultrasound Obstet Gynecol. 2017;49(6):721-8.

Hui L. Noninvasive prenatal testing for aneuploidy using cell-free DNA - New implications for maternal health. Obstet Med. 201;9(4):148-52.

Scott FP, Menezes M, Palma-Dias R, Nisbet D, Schluter P, da Silva Costa F et al. Factors affecting cell-free DNA fetal fraction and the consequences for test accuracy. J Matern Fetal Neonatal Med. 2018;31(14):1865-72.

Benn P, Plon SE, Bianchi DW. Current Controversies in Prenatal Diagnosis 2: NIPT results suggesting maternal cancer should always be disclosed. Prenat Diagn. 2019;39(5):339-43.

Wang Y, Chen Y, Tian F, Zhang J, Song Z, Wu Y, Han X et al. Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem. 2014;60(1):251-9.

Hui L, Bethune M, Weeks A, Kelley J, Hayes L. Repeated failed non-invasive prenatal testing owing to low cell-free fetal DNA fraction and increased variance in a woman with severe autoimmune disease. Ultrasound Obstet Gynecol. 2014;44(2):242-3.

Grömminger S, Erkan S, Schöck U. The influence of low molecular weight heparin medication on plasma DNA in pregnant women. Prenat Diagn. 2015;35:1155-7.

Uldbjerg N. No-call non-invasive prenatal testing gives important information. Int J Obstet Gynaecol. 2018;125(7):856.

Benn P, Valenti E, Shah S, Martin K, Demko Z. Factors Associated With Informative Redraw After an Initial No Result in Noninvasive Prenatal Testing. Obstet Gynecol. 2018;132(2):428-35.

Norton ME, Biggio JR, Kuller JA, Blackwell SC. The role of ultrasound in women who undergo cell-free DNA screening. Am J Obstet Gynecol. 2017;216(3):B2-7.